Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,916 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,498
Recruiting: 782
Ph III recruiting: 85
Growth YoY: +17.8%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 151–200 of 484 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04730219	Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma	unknown	Phase 2	48	Tianjin Medical University Second HospitalOTHER	1	Nov 30, 2022	clinicaltrials
NCT05456074	Integrative Molecular Characterization Of MiT Family Translocation Renal Cell Carcinomas (IMCOR)(IMCOR)	unknown	—	600	Institut de cancérologie Strasbourg EuropeOTHER	1